Cancer and Blood Disorders
Show Only Open Trials
1.
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
- Study Status: Open to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
- Protocol ID: MPD-RC 111
2.
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)
- Study Status: Open to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Polycythemia Vera (PV)
3.
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
4.
Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML)
5.
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: Plexxikon
6.
CALGB 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: CALGB 50901
7.
A Phase II Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Subjects with Newly Diagnosed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Newly Diagnosed Multiple Myeloma; No Previous Treatment
8.
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML) with Core Binding Factor Abnormaility
- Protocol ID: CALGB 10801
9.
CALGB 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
- Study Status: Open to Enrollment
- Sponsor: CALGB
10.
S1108: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
- Study Status: Open to Enrollment
- Sponsor: SWOG
- Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell non-Hodgkin Lymphoma
11.
Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
12.
Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
- Study Status: Open to Enrollment
- Sponsor: Calistoga
- Disease Status and/or Stage: Refractory Indolent B-cell non-Hodgkin Lymphoma
13.
CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: CALGB 50904
14.
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Untreated or Relapsed Chronic Lymphocytic Leukemia
15.
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo diffuse Large B-Cell Lymphoma (PCYC 1106)
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics
- Disease Status and/or Stage: Relapsed or Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL)
16.
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Relapsed or Refractory Lymphoma (non-Hodgkin and Hodgkin)
17.
Clinical Database and Tissue Repository Collection Project for the Study of Waldenstrom's Macroglobulinemia
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
18.
BMS CA204004: A Phase 3, Randomized, Open-Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
19.
Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress)
- Study Status: Open to Enrollment
- Sponsor: Agency for Healthcare Research and Quality; Weill Cornell Medical College
20.
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
- Study Status: Open to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
21.
REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
- Study Status: Open to Enrollment
- Sponsor: Oncolytics Biotech, Inc.
- Disease Status and/or Stage: Colon Cancer
22.
CALGB 11001: A Phase II Study Incorporating Sorafenib Into The Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: FLT3 Mutated Acute Myeloid Leukemia
23.
CALGB 11002 - A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia
24.
NCI 8977: Phase 2 Trial of R11577 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
- Study Status: Open to Enrollment
- Sponsor: National Cancer Institute
- Disease Status and/or Stage: Acute Myeloid Leukemia
25.
REO 017: A Phase 2 Study of Reolysin® in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Advanced or Metastatic Pancreatic Cancer
26.
A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects with Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
- Study Status: Closed to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Advanced/Metastatic Renal Cell Carcinoma (RCC)
27.
A Phase II Study of Tetrathiomolybdate (TM) in patients with breast cancer at moderate to high risk of recurrence
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: High-Risk Stage II Breast Cancer; Stage III Breast Cancer; Stage IV Breast Cancer in Remission
28.
S0221: Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
- Study Status: Closed to Enrollment
- Sponsor: SouthWest Oncology Group (SWOG) and The Cancer Support Trials Unit (CTSU)
- Disease Status and/or Stage: Operable Stage 1, II or II Invasive Breast Cancer
29.
Prospective Data Collection Among Women Using Cold Caps During TC Chemotherapy
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Early-Stage Breast Cancer
30.
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy
- Study Status: Open to Enrollment
- Sponsor: Lilly
- Disease Status and/or Stage: Stage IV Non-Small Cell Lung Cancer
31.
A Phase 1b Safety Study of Abiraterone Acetate (JNJ 212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (COU-AA-206)
- Study Status: Open to Enrollment
- Sponsor: Cougar Biotechnology
- Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
32.
33.
Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated Mantle Cell Lymphoma
34.
Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Diffuse Large B-Cell Lymphoma (DLBCL)
35.
Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
36.
A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics, Inc.
37.
A Phase II Study of Dexamethasone (Decadron), Clarithromycin (Biaxin), and Pomalidomide (CC-4047) for Subjects with Relapsed or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
38.
A Phase 1/2 Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Untreated Multiple Myeloma
39.
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mutliple Myeloma
40.
An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
41.
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Genentech
- Disease Status and/or Stage: Previously Treated t(4;14)-positive Multiple Myeloma
42.
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
43.
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
- Study Status: Closed to Enrollment
- Sponsor: New York Cancer Consortium
- Disease Status and/or Stage: Gastric or Gastroesophageal Junction (GEJ) Cancer Not Amenable to Surgical Resection
44.
A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
45.
An Open-Label Phase I Study of BB-10901 (IMGN901, huN901-DM1) in Combination with Lenalidomide and Dexamethasone in Patients with CD56- positive Relapsed or Relapsed/Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: ImmunoGen, Inc.
46.
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Onyx Therapeutics
47.
Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Follicular Lymphoma
48.
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
- Study Status: Open to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Previously untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
49.
Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
50.
CALGB 50803: A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813, IND#70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
51.
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics
- Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
52.
A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Study Status: Open to Enrollment
- Sponsor: Tragara Pharmaceuticals
- Disease Status and/or Stage: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or High-risk Myelodysplasia (MDS)
53.
Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematological Malignancies
54.
A Phase I/II Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)
- Study Status: Open to Enrollment
- Sponsor: New York Cancer Consortium; National Cancer Institute
- Disease Status and/or Stage: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukemia
55.
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
- Study Status: Open to Enrollment
- Sponsor: Sunesis Pharmaceuticals
- Disease Status and/or Stage: Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia
56.
Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine
- Study Status: Open to Enrollment
- Sponsor: Onconova Therapeutics, Inc
- Disease Status and/or Stage: Myelodysplastic Syndromes (MDS) Including RAEB and Chronic Myelomonocytic Leukemia (CMML)
57.
CALGB 10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
- Study Status: Open to Enrollment
- Sponsor: CALGB; NCI; Eastern Cooperative Oncology Group; Southwest Oncology Group
- Disease Status and/or Stage: Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
- Protocol ID: CALGB 10403
58.
A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence
- Study Status: Open to Enrollment
- Sponsor: Celgene Corporation
- Disease Status and/or Stage: Primary Myelofibrosis
59.
A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia
- Study Status: Open to Enrollment
- Sponsor: Clavis Pharma
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML)
60.
A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- Study Status: Open to Enrollment
- Sponsor: SuperGen
- Disease Status and/or Stage: Intermediate-2 or high-risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
61.
BMT CTN 0701: A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response
- Study Status: Open to Enrollment
- Sponsor: National Heart, Lung and Blood Institute (NHLBI); National Cancer Institute
- Disease Status and/or Stage: Relapsed Follicular Non-Hodgkin's Lymphoma
62.
Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Multiple Myeloma
63.
Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated Hodgkin Lymphoma
64.
Phase 1 Study of Radiosensitization using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma receiving Radioimmunotherapy
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Non-Hodgkin's Lymphoma
65.
Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas
- Study Status: Open to Enrollment
- Sponsor: National Cancer Institute
- Disease Status and/or Stage: Relapsed or Refractory Mantle Cell or Diffuse Large B-Cell Lymphoma
66.
A Phase II, Single Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel®) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
67.
CALGB 50303: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B; National Cancer Institute
- Disease Status and/or Stage: Untreated De Novo Diffuse Large B-Cell Lymphoma with Stage II, III or IV Disease
68.
Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) of Any Stage
69.
CALGB 50401: A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid, CC-5013) (IND #73034) vs. Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) After Relapse from a Rituximab-Containing Regimen
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B; National Cancer Institute
- Disease Status and/or Stage: Recurrent Follicular Non-Hodgkin's Lymphoma
70.
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
- Study Status: Closed to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: Polycythemia Vera (PV)
71.
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Imtermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
72.
Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies
- Study Status: Closed to Enrollment
- Sponsor: Weill Cornell Medical College; Immunomedics, Inc.
73.
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies
- Study Status: Closed to Enrollment
- Sponsor: Calistoga Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
74.
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: High Risk, Clinically Localized Prostate Cancer
75.
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Castration-Resistant Prostate Cancer
76.
Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using 177Lu-J591 Antibody: Dose Fractionation Regimen
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
77.
A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients with Metastatic Androgen-Independent Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic, Hormone-Refractory Prostate Cancer
78.
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed Prostate Cancer
79.
A Phase I Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
80.
A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
- Study Status: Open to Enrollment
- Sponsor: Radiation Therapy Oncology Group, National Cancer Institute
- Disease Status and/or Stage: Prostate Cancer After Radical Prostatectomy
81.
A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
- Study Status: Closed to Enrollment
- Sponsor: BiPar Sciences
- Disease Status and/or Stage: Metastatic Pancreatic Cancer
82.
A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.
- Study Status: Closed to Enrollment
- Sponsor: Immunomedics, Inc.
- Disease Status and/or Stage: Untreated Advanced Pancreatic Cancer
83.
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Study Status: Open to Enrollment
- Sponsor: GlaxoSmithKline
- Disease Status and/or Stage: Ovary, Primary Peritoneal or Fallopian Tube Cancer
84.
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxila) in Patients with Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated with a Taxane
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Advanced Epithelial Ovarian Cancer or Peritoneal Cancer
85.
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
- Study Status: Open to Enrollment
- Sponsor: Tragara Pharmaceuticals
- Disease Status and/or Stage: Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer
86.
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)
- Study Status: Open to Enrollment
- Sponsor: Eli Lily & Co.
- Disease Status and/or Stage: Unresectable, Locally Advance, Stage III Non-Small Cell Lung Cancer
87.
CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: Non-small Cell Lung Cancer
88.
A Phase I/II Study of Vorinostat in Combination with Isotretinoin in the Treatment of Patients with Advanced Renal Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College, National Cancer Institute
- Disease Status and/or Stage: Metastatic or Advanced Kidney Cancer
89.
A Phase I/II Trial of BAY 43-9006 plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College, National Cancer Institute
- Disease Status and/or Stage: Advanced, Unresectable and/or Metastatic Kidney Cancer
90.
ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)
- Study Status: Closed to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
- Disease Status and/or Stage: Renal Cell Cancer
91.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Open to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
92.
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI)
- Disease Status and/or Stage: Advanced Transitional Cell Carcinoma
93.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
94.
A Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1
- Study Status: Closed to Enrollment
- Sponsor: Celldex Therapeutics
- Disease Status and/or Stage: Progressive Disease after therapies with curative potential or approved salvage regimen
95.
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients with Advanced Breast Cancer
- Study Status: Open to Enrollment
- Sponsor: Eisai
- Disease Status and/or Stage: Advanced Breast Cancer and Neuropathy
96.
E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
- Study Status: Open to Enrollment
- Sponsor: Eastern Cooperative Oncology Group; National Cancer Institute
- Disease Status and/or Stage: Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
97.
A Phase I-II Study of R115777 (Tipifarnib, Zarnestraâ) Plus Sequential Weekly Paclitaxel followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer
- Study Status: Open to Enrollment
- Sponsor: New York Cancer Consortium; National Cancer Institute
- Disease Status and/or Stage: Stage IIB-IIC Breast Cancer
98.
Phase II study of ixabepilone in patients with metastatic breast cancer and a prospective evaluation of its effects on the ultrastructure of neurons
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College; Bristol-Myers Squibb
- Disease Status and/or Stage: Metastatic Breast Cancer
99.
ACOSOG Z1072: A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma
- Study Status: Open to Enrollment
- Sponsor: American College of Surgeons/National Cancer Institute
- Disease Status and/or Stage: Invasive Breast Cancer
100.
A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
- Study Status: Closed to Enrollment
- Sponsor: GlaxoSmithKline
- Disease Status and/or Stage: Metastatic Breast Cancer
101.
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism (VTE) in Patients with Cancer
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Any Stage of Cancer
102.
A Randomized Placebo-Controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients with a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Breast Cancer, any stage
103.
A Phase II Study of Tetrathiomolydate (TM) in patients with breast cancer at moderate to high risk for recurrence
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Breast Cancer at moderate to high risk of recurrence (based on the number of lymph nodes); Stage 4 breast cancer without any evidence of disease
